A randomized, double-blind, placebo-controlled, parallelgroup, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis. Evaluate the efficacy of itepekimab compared with placebo on occurrence of pulmonary exacerbations (PEs) in non-cystic fibrosis bronchiectasis (NCFB).
